Overview
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2012-04-01. Active
94 1240 2294 1111 0010 7434 0199- 68 1240 4432 1787 0010 4171 5977
- 33 1240 2294 1111 0010 6826 9194
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
34 public aid cases recorded, with a total value of $4,589,015.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | Regional investment aid | $645,794 | MAŁOPOLSKI URZĄD SKARBOWY W KRAKOWIE | |
| Apr 2, 2024 | Regional investment aid | $588,325 | MAŁOPOLSKI URZĄD SKARBOWY W KRAKOWIE | |
| Jun 30, 2023 | Regional investment aid | $381,441 | MAŁOPOLSKI URZĄD SKARBOWY W KRAKOWIE |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2017-09-01 | Wdrożenie innowacyjnej metody otrzymywania substancji o aktywności farmakologicznej na drodze łagodnego trifluorometylowania | $417,051 | Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020 | |
| 2017-07-01 | Opracowanie platformy badań in vitro dla biopodobnych przeciwciał o działaniu terapeutycznym | $667,433 | Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020 | |
| 2016-01-01 | Opracowanie nowych metod otrzymywania amin chiralnych na potrzeby przemysłu farmaceutycznego | $520,362 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Waste generation | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company may be represented by two members of the management board acting jointly, or by a member of the management board acting jointly with one of the joint commercial proxies.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 2,900 | $78,336.03 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Paweł Tadeusz Przewięźlikowski (54)  | Posiadanie pośrednie przez selvita s.a., w której posiada 16,03% akcji oraz 26,90% głosów, selvita s.a. posiada 100% udziałów w selvita services sp. z o.o. |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| MedappS.A. | $3,351,163.61 | medapp.pl | |
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | |
| EIT Rawmaterials Clc Eastsp. z o.o. | $1,795,803.10 | eitrawmaterials.eu | |
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | |
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | |
| Przedsiębiorstwo Wielobranżowe Genezasp. z o.o. | $54,163.54 | geneza.eu | |
| Medtransfersp. z o.o. | $21,666.01 | codete.com | |
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | |
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | |
| Ncage TherapeuticsS.A. | $29.14 | ncage.org |
Change history
| Date | Event |
|---|---|
| 2019-11-29 | Share capital change (250,000.00 PLN → 290,000.00 PLN) |
| 2015-09-17 | PKD change (Removed: 01.28.Z, 01.29.Z, 01.30.Z, 01.49.Z, 01.61.Z, 01.62.Z, 01.64.Z, 10.89.Z, 20.20.Z, 20.41.Z, 20.42.Z, 26.20.Z, 32.50.Z, 38.11.Z, 38.12.Z, 38.21.Z, 38.22.Z, 39.00.Z, 46.51.Z, 46.75.Z, 47.91.Z, 47.99.Z, 49.41.Z, 52.10.B, 52.21.Z, 58.19.Z, 58.29.Z, 62.0, 63.11.Z, 63.12.Z, 63.91.Z, 63.99.Z, 68.10.Z, 68.20.Z, 68.3, 68.32.Z, 70.21.Z, 70.22.Z, 71.20.A, 73.1, 77.33.Z, 77.39.Z, 77.40.Z, 78.10.Z, 82.11.Z, 82.99.Z, 85.59.B, 85.60.Z, 86.90.D, 86.90.E) |
| 2011-12-01 | Entered in the register |
FAQ
Last updated: 2026-04-21